TAG:
managed care contracts
Smaller Pathology Groups Explore Consolidation
By Robert Michel | From the Volume XVIII No. 5 – April 11, 2011 Issue
CEO SUMMARY: In eastern Washington State, InCyte Pathology is developing a strategy that may well be repeated many times over in the coming years. As older pathologists who run smaller groups look to retire, they will consider selling their group practices to larger entities inte…
Pathology Group Establishes Lab Test Exchange Networks
By Robert Michel | From the Volume XVII No. 4 – March 21, 2011 Issue
CEO SUMMARY: After several decades of steadfastly maintaining their independence from other pathology groups in their community, progressive hospital-based pathology groups are beginning to create regional laboratory testing networks. These collaborations generally start small an…
Seeking Market Clout, Labs Form Networks
By Robert Michel | From the Volume XVIII No. 3 – February 28, 2011 Issue
CEO SUMMARY: Meet “Test Exchange Networks!” These are shared laboratory testing networks that have spontaneously appeared in different communities across the nation. Typically two or more local laboratories come together and begin to collaborate by sharing any number of resources. The…
How Could So Many Labs Violate California Law?
By Robert Michel | From the Volume XVII No. 18 – December 27, 2010 Issue
CEO SUMMARY: If a 40-year-old state law on Medi-Cal pricing was known to regulators and clinical laboratories alike, how did the legal and compliance departments of so many laboratories—staffed by some of the smartest legal minds in California and nationally—interpret the law…
FTC Opposes LabCorp’s Acquisition of Westcliff
By Robert Michel | From the Volume XVII No. 17 – December 6, 2010 Issue
CEO SUMMARY: On November 30, FTC commissioners filed an administrative complaint opposing Laboratory Corporation of America’s acquisition of Westcliff Medical Laboratories, Inc., on the grounds that it “violates antitrust laws and would lead to higher prices and lower quality…
Payers Move to Pre-Authorize Expensive Genetic Tests
By Robert Michel | From the Volume XVII No. 13 – September 13, 2010 Issue
CEO Summary: Pre-authorization of expensive genetic and molecular tests is fast-becoming a priority for most of the nation’s health insurers. For clinical labs and pathology groups that don’t respond, this trend is a threat. On the other hand, because payers need all the skil…
Specimen Volume Declines Reported By Quest Diagnostics and LabCorp
By Robert Michel | From the Volume XVII No. 11 – August 2, 2010 Issue
IN REPORTING SECOND QUARTER EARNINGS, there was enough difference in the numbers announced by Quest Diagnostics Incorporated and Laboratory Corporation of America to catch the attention of financial analysts. Revenue at LabCorp was up for the quarter while revenue a…
Did Wrong Strategy Sink Westcliff Medical Labs?
By Robert Michel | From the Volume XVII No. 8 – June 1, 2010 Issue
CEO SUMMARY: All sorts of people will argue all sorts of opinions about the financial demise of BioLabs, Inc., and its subsidiary, Westcliff Medical Laboratories, Inc., and why it ended up in a California bankruptcy court. Documents filed in the case indicate that, from the birth…
Pre-authorization Coming For Pricey Molecular Tests
By Robert Michel | From the Volume XVII No. 6 – April 19, 2010 Issue
CEO SUMMARY: In response to the steep ramp-up in the utilization of genetic and molecular testing, the nation’s largest health insurers are preparing to institute new guidelines for coverage and reimbursement. These will include pre-authorization by physicians, a more effective genetic …
February 15, 2010 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVII No. 3 – February 15, 2010 Issue
In response to the sky-rocketing expenses associated with genetic and molecular testing, health insurers are planning ways to control both utilization and the prices at which these tests are reimbursed. For example, during the past year, Humana began using DNA Direct …
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized